| 1 |
Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: Long-term follow-up and review of the literature |
|
| | Jovancevic, B. and Lindholm, C. and Pullerits, R. | | | Lupus. 2013; 22(7): 664-674 | | | [Pubmed] [Google Scholar] | | | 2 |
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis |
|
| | Tun, N.M. and Villani, G.M. | | | Journal of Thrombosis and Thrombolysis. 2012; 34(3): 347-359 | | | [Pubmed] [Google Scholar] | | | 3 |
Application of biological agents for treatment of patients with systemic lupus erythematosus [Zastosowanie leków biologicznych w terapii tocznia rumieniowatego układowego] |
|
| | Kramza, J. and Kucharz, E.J. | | | Reumatologia. 2011; 49(4): 264-274 | | | [Pubmed] [Google Scholar] | | | 4 |
Targeting B cells to treat systemic lupus erythematosus |
|
| | Tieng, A.T. and Zandman-Goddard, G. and Peeva, E. | | | International Journal of Clinical Rheumatology. 2010; 5(6): 627-636 | | | [Pubmed] [Google Scholar] | |
|
